Fouremm,

Beyond just the BETonMACE primary outcome on the total population are pre-specified subgroup analyses that include:

– Rosuvastatin vs. Atorvastatin

– < 30 days vs. > 30 days post-acute coronary syndrome

– LDL/HDL/TG’s above and below median

– HbA1c above and below median

– eGFR >60 mL/min and < 60 mL/min

I'm not 100% sure, but I think that the results of these pre-specified subgroup analyses are more likely announced at full CVOT data presentation, and not top-line data reveal. Similarly the results of the renal and cognition studies are more likely announced at a later date after primary outcome top-line. After they officially lock the trial database, then Resverlogix and the Clinical Steering Committee can analyze the unblinded data. The more info they want to pack into top-line data announcement, the longer it will take. First, things first. Hit 250 events and stop dosing. Then complete final patient visits and adjudication. Then database lock and analysis. ACC 2019 LBCT looks unlikely at this point, assuming no news on hitting 250 events means that it hasn't happened yet.

BearDownAZ